Why Is INDIVIOR PHARMACEUTI (INDV) Stock Down Today?
By the Top Tier Newswire AI Desk · August 4, 2026 at 12:11 AM ET · reviewed against 17 wire stories
INDIVIOR PHARMACEUTI (INDV) is down -6.60% in the latest session. Our newswire has captured 17 stories on INDV across 10 sources in the last 36 hours, with AI sentiment reading bullish (avg 63/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
INDV stock fell 6.60% to $37.37 in afternoon trading as the market digested the implications of a proposed merger between Indivior and Supernus Pharmaceuticals. The stock had risen sharply in pre-market trading following strong Q2 results and an upgraded 2026 outlook, but the merger announcement introduced uncertainty about the combined entity's strategic direction and shareholder value.
What Happened
The merger, announced in a joint conference call, is structured as a tax-free all-stock deal that would combine Indivior and Supernus into a central nervous system-focused biopharmaceutical company with pro forma revenues of $2.2 billion. The deal is expected to generate $125 million in annual cost synergies. Indivior shareholders will receive a one-time special cash dividend of $1 billion immediately prior to the closing. The merger is being described as a "merger of equals," though the terms and valuation of the combined entity remain under scrutiny. While the companies highlighted the potential for immediate scale and operational efficiencies, some analysts and investors have expressed skepticism about the long-term value proposition of the deal.
What The Data Shows
Over the past eight trading sessions, the stock has declined 1.1% from $40.45 to $40.01. Recent insider transactions show three sales totaling $2.8 million, with the most recent filing on July 13. Congressional trades include two buys and two sells in the last 90 days. The stock currently trades at a 52-week low of $37.37, down from its high of $42.81. With a market cap of $4.9 billion, a P/E ratio of 20.5, and a beta of 1.15, the stock remains sensitive to broader market movements.
What To Watch
Investors should monitor the expected closing of the merger and the combined entity's integration plan. The deal is expected to close in the coming months, though regulatory and shareholder approvals remain pending.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
INDV · Aug 4 session (5-min) · -2.35% vs prior close · updated 8:55 PM ETAI sentiment, last 36h · averaged over 17 stories · 63/100 bullish
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
7d agoSeeking AlphaBULLISH 63M&A
Supernus And Indivior Merger: There May Be Some Skepticism, But I Have Faith In This Deal
Supernus Pharmaceuticals will merge with Indivior in a tax-free all-stock deal, creating a CNS-focused company with $2.2bn pro forma revenues. Read more here.
7d agoMarketChameleonBULLISH 65M&A
SUPN and Indivior to Merge: $2.2 Billion CNS Giant to Unlock $125 Million in Annual Cost Synergies
Supernus Pharmaceuticals and Indivior Pharmaceuticals are joining forces, forming a $2.2 billion diversified CNS biopharmaceutical leader. The deal, structured as a merger of equals, promises immediate scale, $125 million in annual cost savings, and a robust platform for long-term growth and innovation.
7d agoYahoo FinanceBULLISH 65M&A
Indivior Q2 Earnings Call Highlights
Supernus Pharmaceuticals and Indivior (NASDAQ:INDV) announced plans to combine in an all-stock, tax-free merger of equals that the companies said would create a central nervous system-focused biopharmaceutical company with approximately $2.2 billion in pro forma trailing-12-month net revenue. The t
7d agoTipRanksBULLISH 55M&A
Supernus and Indivior Announce Proposed Stock-for-Stock Merger
Supernus Pharmaceuticals ( ($SUPN) ) has shared an update. On August 3, 2026, Supernus Pharmaceuticals and Indivior Pharmaceuticals held a joint conference call and...
7d agoTipRanksBULLISH 55M&A
Indivior and Supernus announce tax-free merger of equals
The latest announcement is out from Indivior ( ($INDV) ). Indivior Pharmaceuticals, Inc. is a biopharmaceutical company focused on central nervous system disorders,...
7d agoInvestorsHubBULLISH 73Earnings
Indivior Shares Surge After Strong Quarterly Results and Higher 2026 Outlook
Indivior beat second-quarter earnings and revenue estimates, raised its 2026 guidance and reported record SUBLOCADE sales, sending shares sharply higher in pre-market trading.
7d agoInvestorsHubBULLISH 73M&A
Supernus Shares Jump After Revenue Beat, Higher Guidance and Indivior Merger Announcement
Supernus beat second-quarter revenue estimates, raised its 2026 guidance and announced a merger with Indivior, sending shares sharply higher despite an earnings miss driven by a non-cash impairment charge.
7d agoMarketChameleonBULLISH 73Earnings
Indivior Delivers Record Q2 Results With 111% EBITDA Growth and Raises Full-Year Outlook
August 3, 2026
Indivior posts a record-breaking second quarter for 2026 marked by 111% EBITDA growth year-over-year, driven by outstanding SUBLOCADE performance and disciplined expense control. The company raises its full-year guidance and positions itself for a proposed merger with Supernus.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →